Hypertension最新文献

{"title":"Shiny and Mobile Apps for Estimating Blood Pressure Percentiles in Children.","authors":"Laura Montelisciani,Bernard Rosner,Joseph Flynn,Laura Antolini,Marco Giussani,Giacomo Pucci,Simonetta Genovesi","doi":"10.1161/hypertensionaha.125.25087","DOIUrl":"https://doi.org/10.1161/hypertensionaha.125.25087","url":null,"abstract":"BACKGROUNDThe American Academy of Pediatrics, the European Society of Hypertension, and the European Society of Cardiology propose distinct hypertension classification criteria for children and adolescents based on 2 percentile derivations and different fixed blood pressure thresholds at different ages, leading to potential confusion in clinical and research settings.METHODSWe developed 2 Shiny apps and 1 mobile app that allow simultaneous calculation of blood pressure percentiles using both methods and classify hypertension according to each guideline. The first Shiny app was designed for research purposes, offering an efficient tool for handling large pediatric data sets. The second Shiny app and the mobile app are designed for clinical use, presenting the same relevant outcomes for individual patients in a user-friendly interface. The research-focused app was tested on 3 data sets varying in age, blood pressure, and weight distributions.RESULTSWhen comparing the 3 hypertension classifications across the samples, the American Academy of Pediatrics and European Society of Cardiology criteria consistently identified more individuals as hypertensive than the European Society of Hypertension across all age and weight groups, resulting in discordance rates from 2.3% to 21.1%. In contrast, the American Academy of Pediatrics and the European Society of Cardiology showed high agreement, with minimal or absent discordance ranging from 0.0% to 4.4%. An exception was seen in ages of 13 to 16 years, where differing criteria led to greater and unpredictable discordance.CONCLUSIONSThese apps offer researchers and clinicians powerful tools to calculate blood pressure percentiles and hypertension classifications based on different guidelines. This marks an important first step toward identifying which classification best predicts clinical outcomes.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"7 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","authors":"Daniel W Jones, Keith C Ferdinand, Sandra J Taler, Heather M Johnson, Daichi Shimbo, Marwah Abdalla, M Martine Altieri, Nisha Bansal, Natalie A Bello, Adam P Bress, Jocelyn Carter, Jordana B Cohen, Karen J Collins, Yvonne Commodore-Mensah, Leslie L Davis, Brent Egan, Sadiya S Khan, Donald M Lloyd-Jones, Bernadette Mazurek Melnyk, Eva A Mistry, Modele O Ogunniyi, Stacey L Schott, Sidney C Smith, Amy W Talbot, Wanpen Vongpatanasin, Karol E Watson, Paul K Whelton, Jeff D Williamson","doi":"10.1161/HYP.0000000000000249","DOIUrl":"10.1161/HYP.0000000000000249","url":null,"abstract":"<p><strong>Aim: </strong>The \"2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults\" retires and replaces the \"2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.\"</p><p><strong>Methods: </strong>A comprehensive literature search was conducted from December 2023 to June 2024 to identify clinical studies, reviews, and other evidence performed on human subjects that were published since February 2015 in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.</p><p><strong>Structure: </strong>The focus of this clinical practice guideline is to create a living, working document updating current knowledge in the field of high blood pressure aimed at all practicing primary care and specialty clinicians who manage patients with hypertension.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"e212-e316"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Blood Pressure Response Patterns to Exercise Stress Testing.","authors":"Aishwarya Nene, Dana Lee, Olayinka Agboola, Jeph Herrin, Oyere K Onuma, Attila Feher, Edward J Miller, Yuan Lu, Judith L Meadows, Erica S Spatz","doi":"10.1161/HYPERTENSIONAHA.124.23717","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23717","url":null,"abstract":"<p><strong>Background: </strong>A hypertensive response to exercise unmasks hypertension and is associated with future cardiovascular events. Yet, there is heterogeneity in blood pressure response patterns to exercise by age and sex, and some high-risk trajectories may go undetected if only focusing on peak blood pressure.</p><p><strong>Methods: </strong>We analyzed blood pressure data from 13 945 patients who underwent a Bruce protocol exercise tolerance test between 2016 and 2020, including the rate of change across stages. We used latent class analysis to identify distinct blood pressure trajectories and assessed their association with individual and composite outcomes of myocardial infarction, stroke, heart failure, revascularization, and death.</p><p><strong>Results: </strong>Women had lower mean systolic and diastolic blood pressure at rest (128 mm Hg versus 132 mm Hg; 78 mm Hg versus 80 mm Hg) and through stages 1 to 3 of the Bruce protocol (stage 1: 140 mm Hg versus 144 mm Hg; 78 mm Hg versus 80 mm Hg; stage 2: 153 mm Hg versus 157 mm Hg; 79 mm Hg versus 81 mm Hg; stage 3: 159 mm Hg versus 167 mm Hg; 80 mm Hg versus 82 mm Hg). Systolic blood pressure increased more slowly in women. Three distinct systolic blood pressure trajectories emerged, with steeper trajectories associated with older populations and men. Systolic Classes II and III, characterized as an elevated baseline and a gradual rise (Class II) and a steep rise (Class III) with exercise, were associated with cardiovascular outcomes. Yet, only 1.4% and 34% of patients in Class II and III, respectively, met traditional criteria for hypertensive response to exercise, suggesting missed opportunities for prevention and treatment.</p><p><strong>Conclusions: </strong>Blood pressure response to exercise varies by sex; models incorporating trajectories of blood pressure could more fully capture individuals at higher risk for future cardiovascular events.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"1663-1674"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elastin Regulation of Vasoreactivity in Resistance Arteries.","authors":"Claire A Ruddiman,Brooke L O'Donnell,Abigail Wolpe,Nyla Blagrove,Luke S Dunaway,Chien-Jung Lin,Angela K Best,Miriam Cortese-Krott,Robert P Mecham,Jessica Wagenseil,Brant E Isakson","doi":"10.1161/hypertensionaha.124.24372","DOIUrl":"https://doi.org/10.1161/hypertensionaha.124.24372","url":null,"abstract":"BACKGROUNDEndothelial cells (ECs) are the primary producers of elastin in the internal elastic lamina (IEL) of resistance arteries. These arteries have distinct gaps in their IEL where ECs facilitate heterocellular communication with smooth muscle in a signaling microdomain termed the myoendothelial junction. However, the contribution of the IEL to vasodilation and blood pressure in resistance arteries is not well understood.METHODSAn endothelial-specific elastin knockout mouse (EC-specific Elnfl/fl/Cre+) was used to alter the IEL and myoendothelial junctions. Myoendothelial junction resident proteins were localized by en face, pressure myography assessed the effect of elastin depletion on vessel dilation, and blood pressure was measured using radiotelemetry.RESULTSUsing single-cell RNA-sequencing, we found Eln mRNA enriched in arterial endothelium. In EC-specific Elnfl/fl/Cre+ mice, the localization of the myoendothelial junction resident protein Hbα (α hemoglobin) becomes diffuse and disorganized. Normally, Hbα regulates eNOS (endothelial nitric oxide synthase) by sequestering NO, promoting endothelial-derived hyperpolarization as the predominant vasodilation mechanism. However, in EC-specific Elnfl/fl/Cre+ mice, Hbα expression and interaction with eNOS are significantly reduced, corresponding to increased NO signaling via acetylcholine dilation. Intact arteries also exhibit decreased smooth muscle contractility with the diminished IEL. These vascular deficiencies suggested a hypotensive phenotype, but EC-specific Elnfl/fl/Cre+ mice's blood pressure was not different from controls.CONCLUSIONSOur findings suggest that elastin deficiency in resistance arteries alters their vasoreactive properties, resulting in poor contraction and dilation. Furthermore, the absence of the holes in the internal elastic lamina mislocalizes Hbα and eNOS in resistance arteries, switching the vasodilatory mechanism from endothelial-derived hyperpolarization to NO signaling, mimicking larger conduit arteries.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"39 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal TRPM3 Channels Regulate Blood Pressure via Tubuloglomerular Feedback and Plasma Volume Control.","authors":"Jorge Rojo-Mencia,Lucía Alonso Carbajo,Marycarmen Arévalo-Martínez,Lucía Benito-Salamanca,Karel Talavera,M Teresa Pérez-García,José Ramón López López,Pilar Cidad","doi":"10.1161/hypertensionaha.125.25790","DOIUrl":"https://doi.org/10.1161/hypertensionaha.125.25790","url":null,"abstract":"BACKGROUNDTRPM3 is a nonselective cation channel activated by heat, osmotic pressure, and neurosteroids. It is highly expressed in sensory neurons, where it integrates thermal, chemical, and inflammatory signals to modulate downstream responses, but is also present in the brain, kidney, and cardiovascular system. This distribution suggests a role in cardiovascular and renal regulation. We hypothesize that TRPM3 channels may play a role in blood pressure (BP) regulation via both vascular and renal mechanisms. Therefore, analysis of the vascular phenotype in Trpm3-KO mice can provide insights into the channel's potential contribution to hypertension development.METHODSBP was monitored noninvasively in conscious wild-type and Trpm3-KO mice under basal conditions and after oral losartan treatment or angiotensin II infusion via osmotic minipumps. TRPM3 expression in vessels and kidney structures was examined using immunofluorescence microscopy and RNAscope with specific cell markers. Ex vivo renal perfusion and pressure myography were used to evaluate vascular responses.RESULTSTrpm3-KO mice showed a ≈5% BP reduction and resistance to angiotensin II-induced hypertension. Urine [Na⁺] was 35% to 50% higher, and plasma volume was 20% lower, suggesting a renal origin of the hypotension. TRPM3 was localized at the juxtaglomerular apparatus and distal nephron segments involved in plasma volume regulation. Trpm3-KO mice exhibited impaired tubuloglomerular feedback, reducing afferent arteriole constriction and NaCl reabsorption.CONCLUSIONSTRPM3 channels contribute to BP regulation by modulating kidney function. Blunted tubuloglomerular feedback in Trpm3-KO mice disrupts NaCl reabsorption, leading to hypovolemia and lower BP. Thus, renal TRPM3 channels may serve as promising targets for BP regulation.","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"99 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension.","authors":"Konstantin A Krychtiuk, Renato D Lopes, Victoria A Cargill, Roland Chen, Martin R Cowie, William C Cushman, Mitchell S V Elkind, Shilpi Epstein, Pushkal P Garg, Bernard J Gersh, Michail Giakoumis, Jennifer B Green, Weinong Guo, Ajay J Kirtane, Marty Lefkowitz, Anastasia Lesogor, George A Mensah, Michelle L O'Donoghue, E Magnus Ohman, Neha J Pagidipati, David Reboussin, Lothar Roessig, Veronique L Roger, Eduardo Sanchez, Norman Stockbridge, Rhian M Touyz, Harriette G C Van Spall, Michael A Weber, Seamus P Whelton, Adrian F Hernandez, Clyde W Yancy, Christopher B Granger","doi":"10.1161/HYPERTENSIONAHA.125.24992","DOIUrl":"10.1161/HYPERTENSIONAHA.125.24992","url":null,"abstract":"<p><p>Hypertension is the single most important modifiable risk factor for preventable disability and death worldwide and disproportionately affects socially disadvantaged populations. We face a paradox-blood pressure control is low and recent trends suggest it is even declining, despite the availability of inexpensive and effective therapies. A variety of barriers on the system, patient, and healthcare provider side hinder effective drug-based risk factor management. Clinical inertia represents a major barrier on the clinician side, as well as workload and limited education. Common barriers on the patient side include limited English proficiency, low health literacy, and nonadherence with misaligned incentives, limited resources, lack of structured clinical pathways, and reimbursement issues. New innovations in the field of RNA-targeted therapies and device-based interventions could prevent and potentially even cure diseases previously designated as chronic health conditions, such as hypertension. Such novel therapies could potentially overcome several major barriers to effective treatment, including nonadherence. Drug development of novel, long-acting treatments requires consideration of specific clinical trial design aspects, including safety collection, benefit: risk assessment, the development and assessment of novel, qualitative surrogate end points, such as time-in-therapeutic range, the use of representative trial settings as well as the definition of standard of care in placebo-controlled trials, which should be of reasonably high-quality allowing for credible evaluation of effectiveness. Here, we provide an overview on barriers to effective treatment and a framework for trials assessing novel treatments for cardiovascular disease risk factors, including early and broad implementation programs.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"1599-1611"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Effect of Cocoa Extract Supplementation on Incident Hypertension.","authors":"Rikuta Hamaya, Sidong Li, Jessica Lau, Matthew Allison, Bernhard Haring, Aladdin H Shadyab, Nudy Matthew, Lisa Warsinger Martin, Pamela M Rist, JoAnn E Manson, Howard D Sesso","doi":"10.1161/HYPERTENSIONAHA.125.25209","DOIUrl":"10.1161/HYPERTENSIONAHA.125.25209","url":null,"abstract":"<p><strong>Background: </strong>Cocoa flavanols have potential blood pressure (BP)-lowering effects in shorter-term, smaller-scale randomized clinical trials, but their effect on incident hypertension has not been examined in a large-scale and long-term randomized clinical trial.</p><p><strong>Methods: </strong>The COSMOS (Cocoa Supplement and Multivitamin Outcomes Study) is a 2×2 factorial, double-blind, placebo-controlled randomized clinical trial testing cocoa extract (including 500 mg/d cocoa flavanols, with 80 mg/d [-]-epicatechin) and a multivitamin among 21 442 women aged ≥65 years and men aged ≥60 years. Placebos did not include any bioactive compounds. In 8905 COSMOS participants free from baseline hypertension, we investigated the effect of cocoa extract on incident hypertension using Cox proportional hazards models. Incident hypertension was defined as self-reported first-time physician diagnosis, initiation of antihypertensive medications, or elevated BP.</p><p><strong>Results: </strong>Mean age at baseline was 71.1 years (SD, 6.2), and 59% were women. Over a median follow-up of 3.4 years, cocoa extract supplementation had no significant effect on incident hypertension in an intention-to-treat analysis, with incidence rates of 7.1 and 7.4 per 100 person-years in cocoa and placebo groups, respectively (hazard ratio, 0.96 [95% CI, 0.88-1.05]). In subgroup analyses, cocoa extract supplementation reduced the incidence of hypertension among participants with baseline systolic BP <120 mm Hg (hazard ratio, 0.76 [0.64-0.90]), but not among those with systolic BP of 120 to 139 mm Hg (hazard ratio, 1.05 [0.93-1.18]; <i>P</i>-interaction=0.002). The effect among baseline systolic BP <120 mm Hg became evident at year 2 after randomization.</p><p><strong>Conclusions: </strong>In older adults, long-term cocoa extract supplementation did not reduce the overall risk of self-reported incident hypertension. However, among those with normal systolic BP at baseline, cocoa extract reduced hypertension risk by 24%.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"1653-1662"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes After Unilateral Adrenalectomy in Asymmetrical Bilateral Primary Aldosteronism.","authors":"Megan C Grundy, Alexander A Leung, Janice L Pasieka, Adrian Harvey, C Benny So, Cori E Caughlin, Stefan J Przybojewski, Dennis J Orton, Martin Hyrcza, Gregory A Kline","doi":"10.1161/HYPERTENSIONAHA.125.24849","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24849","url":null,"abstract":"<p><strong>Background: </strong>Lateralization by adrenal vein sampling (AVS) is the gold standard for diagnosis of unilateral primary aldosteronism. Aldosterone production from the contralateral gland suggests bilateral disease; however, little is known regarding outcomes from patients with grossly elevated (but asymmetrical) contralateral aldosterone production after unilateral adrenalectomy.</p><p><strong>Methods: </strong>A retrospective chart review was performed of cases from the Calgary AVS database with (1) successful AVS (selectivity index ≥3 bilaterally after cosyntropin stimulation); (2) lateralization by AVS (lateralization index ≥3), stimulated or unstimulated; (3) absence of contralateral suppression (contralateral suppression index ≥2 on the nondominant side) stimulated or unstimulated; and (4) underwent unilateral adrenalectomy guided by AVS lateralization. Postsurgical outcomes were classified per PASO criteria.</p><p><strong>Results: </strong>A total of 29 cases met inclusion criteria and underwent unilateral adrenalectomy with postsurgical outcomes available. Of patients with biochemical follow-up data, 20 of 27 had a complete biochemical response and 3 of 27 a partial response (median follow-up time of 10.3 weeks, interquartile range, 4.0-18.3). Four of 29 patients had a complete clinical response, while 18 of 29 patients had a partial clinical response (median follow-up time of 27.3 weeks, interquartile range, 10.7-35.6), such that 75% of patients had either complete or partial clinical response to unilateral adrenalectomy.</p><p><strong>Conclusions: </strong>In patients with bilateral (elevated contralateral suppression index) but asymmetrical primary aldosteronism, unilateral adrenalectomy can achieve positive biochemical and clinical outcomes in the short to mid-term. Elevated contralateral suppression index should not necessarily preclude recommendation of unilateral adrenalectomy in patients with lateralized primary aldosteronism, though longer-term studies are needed to clarify the rates of disease recurrence and benefits of a debulking procedure.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"82 10","pages":"1612-1622"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension Editors' View of the 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.","authors":"David G Harrison, Rhian M Touyz","doi":"10.1161/HYPERTENSIONAHA.125.25467","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.25467","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"82 10","pages":"e193-e195"},"PeriodicalIF":8.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Encouraged by the 2025 US Guidelines to Lower Systolic Blood Pressure Below 120 mm Hg. From Guidelines to Clinical Practice.","authors":"Paolo Verdecchia,Fabio Angeli,Gianpaolo Reboldi","doi":"10.1161/hypertensionaha.125.25902","DOIUrl":"https://doi.org/10.1161/hypertensionaha.125.25902","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"91 1","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}